Board Change • May 20
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Interim CEO & Chairman of the Board David Lontini is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annonce • Sep 15
Check-Cap Ltd., Annual General Meeting, Oct 17, 2025 Check-Cap Ltd., Annual General Meeting, Oct 17, 2025. Location: paul hastings llp, 200 park avenue, ny 10166., new york United States Annonce • Sep 13
MBody AI entered into a definitive Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) in a reverse merger transaction. MBody AI entered into a definitive Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) in a reverse merger transaction on September 12, 2025. The combined company will be renamed “MBody AI Ltd.” The combined company will continue to hold Check-Cap’s legacy assets, consisting primarily of patents and proprietary medical equipment. MBody AI and Check-Cap have also agreed to use commercially reasonable efforts to secure a financing in a private placement on terms reasonably acceptable to each of the parties. Following the closing of the Merger, current MBody AI equityholders will own 90% of the issued and outstanding ordinary shares of the combined company on a fully diluted basis, and current Check-Cap equityholders will own 10% of the issued and outstanding ordinary shares of the combined company on a fully diluted basis. The Merger Agreement may be terminated before the Closing of the Merger (i) by mutual consent, (ii) by either Check-Cap or MBody AI if the Merger fails to consummate by June 30, 2026, (iii) by either Check-Cap or MBody AI if the shareholders of the Company fail to approve the Merger and the related transactions at the Meeting, (iv) by MBody AI if there is an adverse board recommendation of the Check-Cap Board, (v) by either Check-Cap or MBody AI upon a willful and material breach by either party, or (vi) by Check-Cap upon its decision to pursue permitted alternative transactions. In addition, if the Merger Agreement is terminated because the shareholders of the Company fail to approve the Merger at the Meeting, Check-Cap has agreed to reimburse MBody AI up to ILS 8.314 million in expenses, and if the Merger Agreement is terminated for reasons stated in clauses (iv) and (vi) above, Check-Cap has agreed to pay to MBody AI a nonrefundable fee in an amount equal to ILS 4.989 million. The Merger has been approved by the board of directors of both Check-Cap and MBody AI. The Merger is subject to the approval of Check-Cap shareholders at the upcoming Annual General Meeting of Shareholders to be held on October 17, 2025. If the Merger is approved at the meeting. The Closing is expected to take place in the fourth quarter of 2025. Equiniti Trust Company, LLC act as transfer agent for Check-Cap Ltd. Annonce • May 02
Check-Cap Ltd. announced delayed 20-F filing On 05/01/2025, Check-Cap Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Annonce • Apr 16
Check-Cap Ltd. Announces Chief Financial Officer Changes On April 6, 2025, Check-Cap Ltd. appointed Alan Lewis to replace David Benaim as the Company’s Chief Financial Officer. In connection with Mr. Lewis’ appointment as the CFO, the Company entered into a Services Agreement by and between the Company and Mr. Lewis. New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€6.66m market cap, or US$7.37m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change). New Risk • Sep 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.86m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€8.86m market cap, or US$9.89m). Board Change • Aug 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director David Lontini is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • May 03
Check-Cap Ltd. announced delayed 20-F filing On 05/01/2024, Check-Cap Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Mar 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.3m net loss next year). Market cap is less than US$100m (€10.6m market cap, or US$11.5m). Annonce • Mar 26
Nobul AI Corp entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK). Nobul AI Corp entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) on March 25, 2024. Following the transaction, the shareholders of Nobul will become the majority holders of the combined company. If completed, the business combination will create a public company headquartered in Canada. In connection with the transaction, the combined company will apply for listing on the NASDAQ and TSX. Listing will be subject to the satisfaction of all listing requirements and approval of the NASDAQ and TSX. The executive team of Nobul will serve as the executive team of the combined company, led by Regan McGee, Nobul's Founder, Chief Executive Officer and Chairman. The proposed transaction has been approved by the board of directors of both companies. The business combination is subject to the approval of Check-Cap shareholders at a special meeting of shareholders, in accordance with provisions of Israeli Companies Law, along with the satisfaction or waiver of other customary conditions including regulatory and exchange approvals. The special meeting of shareholders is expected to occur in the coming months. Kingswood Capital Partners LLC provided a verbal Fairness Opinion to Check-Cap's Board of Directors and ArcStone Securities and Investment Corp. acted as a financial advisor to Check-Cap in connection with the transaction. Annonce • Jan 26
Check-Cap Ltd. Announces Executive Changes On January 18, 2024, the Board of Directors of Check-Cap Ltd. approved that Mr. Alex Ovadia’s last day as CEO of the Company would be on April 17, 2024. Mr. Alex Ovadia has agreed to help the company through the transition. On January 22, 2024, the Board approved the appointment of Mr. Idan Ben-Shitrit as the Interim Chief Executive Officer (Interim CEO) of the company. Mr. Ben-Shitrit has served as a member of the Board since December 2023 and he will remain a member of the Board following his appointment as Interim CEO. Mr. Ben-Shitrit, 50, has served since 2018 as a board member at multiple privately held companies and as a financial and wealth advisor. From 2020 until 2022, Mr. Ben Shitrit served as a manager at Zim Group Ltd. and from 2018 until 2020 Mr. Ben Shitrit managed a hedge fund named Triton Capital. From 2016 to 2018, Mr. Ben Shitrit worked as an independent investment banker. From 2009 to 2016, he served as a portfolio and securities manager at Expert Nostro Co., Meitav Nostro, and Altris Nostro. In 2007 and 2008, Mr. Ben Shitrit served as an investment manager at Africa Israel Investment Ltd. and from 2005 to 2007, he served as a Department Senior Manager at Michael Davis Group. Prior to 2005, Mr. Ben Shitrit served as a trader at Harel Investment Company. Mr. Ben Shitrit has a Bachelor of Arts’ degree in Mathematics and Economics from Tel-Aviv University and a Master of Business Administration degree from Herzliya Reichman University. Annonce • Jan 25
Check-Cap Ltd. Announces Board Appointments The Board of Directors of Check-Cap Ltd. announced that it appointed Mr. Paul Medeiros, 56, to serve as a director and as the Chairperson of the Board, to hold office until the next annual meeting of shareholders of the Company, or until earlier resignation of removal, to fill an existing vacancy of the Board. Mr. Medeiros, 56, has served as a Managing Director of Consulting and Technical Services at NSF International from November 2015 until April 2022. Prior to, April 2022 he served as a Manager of Environmental Health at Wellington-Dufferin-Guelph Public Health in Ontario, Canada. Mr. Medeiros holds a master’s degree in food safety and quality assurance from the University of Guelph. Mr. Medeiros also has served on the Program Advisory Committees of Toronto Metropolitan University (Ryerson University) since 2014 and Conestoga College since 2016. On January 21, 2024, the Board appointed Mr. Graham Schmidt, 38, to serve as a director of the Company, to hold office until the next annual meeting of shareholders of the Company, or until earlier resignation of removal, to fill an existing vacancy of the Board, as set forth in Article 42 of the Company’s Articles of Association. On January 22, 2024, Mr. Schmidt, notified the Company of his resignation from his position as a member of the Board. Annonce • Jan 12
Check-Cap Ltd. Announces CFO Changes On January 6, 2024, Mrs. Mira Rosenzweig notified Check-Cap Ltd. (“Check-Cap”) of her resignation from her position as a Chief Financial Officer of the Company, effective on April 4, 2024. Mrs. Rosenzwig’s resignation was not related to any disagreement with Check-Cap on any matter relating to its operations, policies or practices. On January 11, 2024, the board of directors (the “Board”) of Check-Cap approved the appointment of Mr. Dan Hilerowitz, CPA, as the Company’s chief financial officer, effective on March 1, 2024 and approved the terms of his compensation. Mr. Hilerowitz, 43, is a certified Public Accountant in Israel and holds a bachelor’s degree in accounting and finance from the College of Management Academic Studies (Rishon Letzion, Israel) and MBA in Accounting and Economics from Tel-Aviv University. Prior to joining Check-Cap, Mr. Hilerowitz served in key financial leadership roles at renowned companies in the industry, demonstrating a keen ability to navigate complex financial landscapes and contribute to overall organizational success. Prior to that, Mr. Hilerowitz served as an accountant and manager at Ernest & Young Tel-Aviv for six years, working with numerous Nasdaq companies. Annonce • Jan 07
Check-Cap Ltd. Announces Resignation of William Vozzolo as Member of the Board of Directors and Independent Member of the Audit Committee On January 3, 2024, Mr. William Vozzolo, notified Check-Cap Ltd. of his resignation from his position as a member of the board of directors and as an independent member of the audit committee of Check-Cap. Annonce • Dec 06
Symetryx Corporation Recommends Shareholders to Vote Against the Keystone Dental Merger and For its Board Nominees On December 5, 2023, Symetryx Corporation announced that it once again encourages its fellow shareholders of Check-Cap Ltd. to review the news release issued by Yoav Kimchy, the Founder and former Chief Technology Officer, and shareholder, of the Company, who has stated in an open letter to his fellow shareholders that the value of the Intellectual Property of the Company was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction. Symetryx Corporation stated that further to its news release of November 28, 2023, Symetryx Corporation continues to urge its fellow Company shareholders to vote against the Keystone Dental and for Symetryx Corporation slate of independent director nominees. Annonce • Nov 29
Symetryx Corporation Discloses its Views on Check-Cap On November 27, 2023, Symetryx Corporation announced that it intends to vote against the unsolicited proposal to merge Check-Cap Ltd. with Keystone Dental and vote for its 5-nominees to the Check-Cap Board of Directors which include: Idan Ben Shitrit, Avital Shafran, Jordan Lipton, William Vozzolo, and Lilian Malczewski. Symetryx Corporation also urges its fellow shareholders to likewise vote against the unsolicited proposal to merge Check-Cap Ltd. with Keystone Dental and to vote for all 5 of Symetryx Corporation’s independent director nominees. New Risk • Nov 29
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$6.3m net loss next year). Market cap is less than US$100m (€17.1m market cap, or US$18.8m). Annonce • Aug 18
SBT Holdings Inc. entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) in a reverse merger transaction. SBT Holdings Inc. entered into a definitive Business Combination Agreement to acquire Check-Cap Ltd. (NasdaqCM:CHEK) in a reverse merger transaction on August 16, 2023. Post completion, current Check-Cap security holders are expected to own approximately 15% of the combined company representing an equity valuation of $39.7 million and Keystone Dental security holders are expected to own approximately 85% of the combined company representing an equity valuation of $225 million. The ownership percentages may be subject to adjustment based on Check-Cap’s net cash at closing. In a related transaction, Capstone Merger Sub Ltd an indirect subsidiary of Keystone will merge with and into Check-Cap Ltd. The combined company will be renamed to Keystone Dental Holdings and will trade on the NASDAQ with the ticker “KSD”. If the agreement is terminated by Check-cap then, Check-Cap shall pay to Keystone a nonrefundable fee in an amount equal to $1,500,000 plus fees and expenses incurred by Keystone in connection with the Transactions not to exceed $1,500,000 as part of termination fees. If the agreement is terminated by Keystone, then Keystone shall pay to Check-Cap, nonrefundable fee in an amount equal to $4,000,000 plus fees and expenses incurred by Check-Cap in connection with the Transactions not to exceed $1,000,000. Check-Cap Ltd. had revenues of $61 million approximately in year 2022. Melker Nilsson, Keystone’s Chief Executive Officer to become Chief Executive Officer of the combined company. If completed, the business combination will create a public company headquartered in Irvine, CA. The business combination is subject to the approval of Check-Cap shareholders and Keystone shareholders. The transaction is subject to approval of Nasdaq stock exchange with respect to listing of the shares. The proposed transaction has been approved by the board of directors of both companies. Concurrently with the execution of the BCA, Lock-up agreement is also entered pursuant to which such officers, directors and stockholders accepted certain restrictions on transfers of the shares of Keystone Common Stock held by such officer, director or stockholder during the period commencing upon closing and ending on the date that is 180 days after the date of closing. The transaction is expected to close in the fourth quarter of 2023. Ladenburg Thalmann & Co. Inc. is acting as financial advisor to Check-Cap. Gary M. Emmanuel and Mark Selinger of Greenberg Traurig and Eran Yaniv and Sharon Rosen of Fischer Behar Chen Well Orion & Co are acting as legal advisor to Check-Cap. Adam M. Klein and Daniel P. Kahn of Goldfarb Seligman & Co. and Joseph Wolfson of Stevens & Lee, P.C. are acting as legal advisor to Keystone. Annonce • Aug 05
Check-Cap Ltd. Reports Impairment of Fixed Assets for the Second Quarter Ended June 30, 2023 Check-Cap Ltd. reported Impairment of fixed assets for the second quarter ended June 30, 2023. For the quarter, Impairment of fixed assets was $1.4 million for the three months ended June 30, 2023. Due to the changes in circumstances that indicate that the carrying amount of an asset may not be recoverable, the Company reviewed its long-lived assets for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets". Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Director Clara Ezed was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Nov 10
Check-Cap Ltd., Annual General Meeting, Dec 22, 2022 Check-Cap Ltd., Annual General Meeting, Dec 22, 2022, at 16:00 Israel Standard Time. Location: Check-Cap Building, 29 Abba Hushi Avenue Isfiya Israel Agenda: To re-elect all five directors as members of our Board of Directors, each to serve until our next annual general meeting of shareholders and until their respective successors are duly elected and qualified; to approve the remuneration to be paid to each of the director nominees, subject to their re-election at the Meeting; to approve a one-time award of options to each of the director nominees, subject to their re-election at the Meeting; to ratify and approve the reappointment of Brightman Almagor Zohar & Co., Certified Public Accountants, a firm in the Deloitte Global Network, as our independent auditor for the year ending December 31, 2022 and for such additional period until our next annual general meeting of shareholders; and to consider any other matters. Annonce • Jun 24
Check-Cap Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement Check-Cap Ltd. announced that on June 22, 2022, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is eligible for an additional 180 calendar day period, or until December 19, 2022, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2) [and 5810(c)(3)(A) on December 23, 2021, and was given until June 21, 2022 to regain compliance. The Company did not regain compliance with the minimum $1 bid price per share requirement during the first 180-calendar-day compliance period and submitted written request to the Staff to afford it an additional 180-day compliance period to cure the deficiency. If at any time before December 19, 2022, the bid price of the Company's ordinary shares closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. Annonce • May 12
Check-Cap Ltd. Announces the Initiation of its U.S. Pivotal Trial of C-Scana at Mayo Clinic in Rochester Minnesota Check-Cap Ltd. announced the initiation of its U.S. pivotal trial of C-Scan® at Mayo Clinic in Rochester Minnesota. The Company has successfully obtained Institutional review board (IRB) approval for the study and expects to promptly begin patient enrollment. Elizabeth Rajan, M.D., gastroenterologist, and professor of medicine at Mayo Clinic, will be the principal investigator of the study at this site. The U.S. pivotal study (NCT05271656) is designed to obtain FDA clearance for C-Scan® in the U.S. The study is a two-part open label trial to evaluate the accuracy of C-Scan to identify subjects who are at elevated risk for colon polyps. It is expected to enroll approximately 1,000 subjects ages 50-75 and will be conducted at up to 15 clinical sites in the U.S. The first part of the trial is designed to enable further calibration of C-Scan for the average risk U.S. population and will enroll up to 200 subjects. The second part consists of a statistically powered, randomized study which will compare the performance of C-Scan to traditional colonoscopy, using sensitivity and specificity measures and will enroll approximately 800 subjects. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Independent Director Clara Ezed was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Feb 08
Check-Cap Ltd. Receives Approval from the U.S. Food and Drug Administration for Its Amended Investigational Device Exemption Application Check-Cap Ltd. announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its amended Investigational Device Exemption (IDE) application, enabling initiation of the U.S. pivotal study. The U.S. pivotal study consists of two parts. The first part is designed to enable further calibration of the system for the average risk U.S. population. The second part will include a statistically powered, randomized study which will compare the performance of C-Scan to traditional colonoscopy. Annonce • Dec 24
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification Check-Cap Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting. The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Check-Cap's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "CHEK". Annonce • Nov 24
Check-Cap Ltd. Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for Its Colorectal Screening Test, C-Scan Check-Cap Ltd. announced the publication of research titled "Colorectal cancer and polyp detection using a new preparation-free colon-scan capsule: A pilot study of safety and patient satisfaction" in the peer-reviewed journal Digestive Diseases and Sciences, which further validates C-Scan's safety and patient satisfaction based on data from its 2019 previously completed U.S. pilot study. In this study there were no serious adverse events or occurrences of capsule retention out of the 40 patients who underwent the study procedure. Of the 87% of patients who completed the satisfaction questionnaires, patients were significantly more likely to recommend the C-Scan capsule, with an average score of 4.1 out of 5 versus a 2.8 out of 5 score for colonoscopy. Check-Cap'sU.S. pilot study was a prospective open label, single arm study that examined C-Scan's safety, usability and subject compliance and evaluated patient satisfaction compared to colonoscopy. The study was conducted at two U.S. sites, the NYU Grossman School of Medicine and Mayo Clinic, Rochester in 2019. 80% of patients were of average risk for colorectal cancer and the mean age was 52.9. Each patient ingested a C-Scan capsule and underwent a comparative colonoscopy, which was performed by an independent gastroenterologist who was blinded to the corresponding test results. Breakeven Date Change • May 21
No longer forecast to breakeven The analyst covering Check-Cap no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of US$11.5m in 2022. New forecast suggests the company will make a loss of US$17.2m in 2022. Annonce • Mar 16
Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® Check-Cap Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is intended for candidates who are at average-risk for CRC and who are poor candidates for colonoscopy or decline colonoscopy, or who had an incomplete optical colonoscopy. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Is New 90 Day High Low • Mar 16
New 90-day high: €2.74 The company is up 938% from a price of €0.26 on 16 December 2020. Outperformed the German market which is up 9.0% over the last 90 days. Exceeded the Medical Equipment industry, which is up 11% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: €1.03 The company is up 241% from its price of €0.30 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 05
New 90-day low: €0.23 The company is down 57% from its price of €0.54 on 06 August 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period. 
